Knopp Neurosciences is developing the right-oriented enantiomer of Parkinson's and restless leg syndrome drug pramipexole (Mirapex) for amyotrophic lateral sclerosis. The drug has received orphan designation from the FDA, and is now in Phase IIa studies in 80 ALS patients.
2100 Wharton Street
Suite 615
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.
